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Background: Various immunotherapeutic approaches have been used for the treatment of cancer. A number of
natural compounds are designed to repair, stimulate, or enhance the immune system response. Among them are the
hemocyanins (Hcs) - extracellular copper proteins isolated from different arthropod and mollusc species. Hcs are
oxygen transporter molecules and normally are freely dissolved in the hemolymph of these animals. Hemocyanins are
very promising class of anti-cancer therapeutics due to their immunogenic properties and the absence of toxicity or
side effects. KLH (Megathura crenulata hemocyanin) is the most studied molecule of this group setting a standard for
natural carrier protein for small molecules and has been used in anti-tumor clinical trials.
Results: The Hcs isolated from marine snail Rapana thomasiana (RtH) and the terrestrial snail Helix pomatia (HpH) express
strong in vivo anti-cancer and anti-proliferative effects in the developed by us murine model of colon carcinoma. The
immunization with RtH and HpH prolonged the survival of treated animals, improve humoral anti-cancer response and
moderate the manifestation of C-26 carcinoma symptoms as tumor growth, splenomegaly and lung metastasis
appearance.
Conclusion: Hemocyanins are used so far for therapy of superficial bladder cancer and murine melanoma models. Our
findings demonstrate a potential anti-cancer effect of hemocyanins on a murine model of colon carcinoma suggesting
their use for immunotherapy of different types of cancer.
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Cancer is one of the major reasons for human death in the
last decade following cardiovascular diseases, infectious dis-
eases and ischemic heart diseases. Current therapies of can-
cer include chemotherapy and radiotherapy although they
both have severe side effects. Each type of cancer requires
specific treatment, which explains the need for develop-
ment of highly specific targeted anti-cancer agents [1].
The BCG (Bacillus Calmette-Guérin) vaccine for tu-
berculosis that contains attenuated Mycobacterium bovis
is one of the most extensively used immunotherapeutics
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unless otherwise stated.properties [2,3]. BCG is widely administrated in cases of
colorectal, lung cancers and melanoma.
In the last years a number of therapeutic antibodies
have been approved for clinical treatment in cases
of breast cancer (Trastuzumab), non-Hodgkin (Rituxi-
mab) and Hodgkin lymphoma (Brentuximab vedotin),
colorectal cancer (Panitumumab, Cetuximab), chronic
lymphocyte leukemia (Alemtuzumab), and acute mye-
logenous leukemia (Gemtuzumab ozogamicin) [4]. Im-
munotherapy with cytokines is another option for
cancer treatment. IL-2 in metastatic melanoma and
renal cell carcinoma and IFN-alpha in Stage III melan-
oma have been permitted for cancer therapy [5].
Different cancer vaccines have been developed for
prevention and treatment of malignant diseases but only
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of the developed vaccines include cancer carbohydrate
antigens chemically conjugated to carrier protein with or
without other adjuvant [7-9].
Today natural products and their compounds derived
from fungi, plants or microbes are of great interest for an
anti-cancer research. This huge variety of chemical struc-
tures provides different mechanisms of action and specific
effects used for anti-tumor therapy.
Marine compounds are known to have a serious poten-
tial as anti-cancer drugs. Most of them are small mole-
cules, inhibitors of key enzymes for carcinogenesis like
matrix metalloproteinazes (MMPs), HIFs, topoisomerase,
protein kinase C (PKC) or transcripion factors like NFkB
[10]. Special attention is payed on marine-derived anti-
angiogenesis products, which suppress and prevent the
succesful formation of vascular system, supporting tumor
growth and invasion. The majority of these substances act
via inhibition of enzymes or factors, crucial for the process
of angiogenesis [11].
Another group of potential anti-cancer agents are the he-
mocyanins (Hcs) - oligomeric copper-containing glycopro-
teins that function as oxygen carriers in the hemolymph of
several molluscs and arthropods. Molluscan Hcs have been
studied intensively for many years with respect to their
structure and function [12]. The huge molecular size (4 to
8 MDa) of molluscan Hcs, their xenogenic character and
carbohydrate content have been implicated in inducing
strong immune response in mammals, which has led to
the biomedical and therapeutic application of these pro-
teins. Thus, keyhole limpet hemocyanin (KLH) isolated
from marine gastropod Megathura crenulata is a well-
established immune stimulant, hapten carrier and tumor
vaccine carrier [13,14].
It is known that Hcs stimulate the immune system non-
specifically by interacting with macrophages, polymorpho-
nuclears, CD4+ and CD8+ cells giving rise to potentFigure 1 Molecular structure of gastropod Hcs. (A) TEM of negatively s
RtH didecamer; side view and top view [21]; (C) scheme of the subunit con
unit RtH2-e [22].humoral and cellular immune response. One possibility
for their anti-cancer effect is that they generally enhance
statement of immune system that helps the immune cells
to recognize self from non-self and to eliminate non-self
cancerous cells. KLH and CCH (Concholepas concholepas
hemocyanin) are intensively studied for their anti-cancer
properties in superficial bladder cancer (SBC) and in
melanoma models [15,16].
Recently, we have demonstrated that the Hc isolated
from marine gastropod Rapana thomasiana (RtH) pos-
sesses a high immunogenicity as a single model antigen
and can be used as a protein carrier for viral peptides from
influenza hemagglutinin [17]. Our results have shown that
RtH is acceptable as a potential bio-adjuvant for subunit
bacterial and viral vaccines [18]. Compared to the numer-
ous studies on the structural organization and protein sta-
bility of the Hc isolated from garden snail Helix pomatia
(HpH), its immunological properties have been less inves-
tigated [19]. These results point on the potential proper-
ties of RtH and HpH as anti-cancer agents.
C-26 murine model of colorectal carcinoma is classical
tumor model, developed in 1975 and determinated as an
undifferentiated Grade IV carcinoma [20]. C-26 cells dis-
play high tumorigenicity and low tendency to metastasize
mainly in the lungs. Inoculated in syngeneic Balb/c mice
C-26 cells cause high mortality. This model is used more
than 35 years for studying the process of carcinogenesis
and anti-cancer therapy.
The aim of the present work was to develop an experi-
mental murine model of colon carcinoma and to investi-
gate the anti-tumor activity of RtH and HpH.
Results
Hemocyanins analysis
Figure 1 presents the synopsis of our results from the
structural studies of the Hc isolated from marine snail R.
thomasiana. The electron micrograph shows typical fortained RtH molecules; (B) 3-D reconstruction of the hollow cylindrical
taining eight different functional units; (D) X-ray structure of functional
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structure of molluscan Hcs is a hollow cylindrical molecule,
about 35 nm in diameter, with an internal collar complex.
3-D reconstruction of the RtH molecule is shown on
Figure 1B [21]. Molecules of molluscan Hcs are structured
as decamers (in cephalopods) or didecamers (in gastropods)
of subunits with molecular mass of 350–450 kDa. The
polypeptide chains of subunits contain seven or eight
globular functional units (FUs), depending on the species.
FUs are generally termed (a - h), starting from the N-
terminus of the respective subunit (Figure 1C). The FUs
have a binuclear copper active site, capable of binding
reversibly one oxygen molecule. The active site consists of
two closely spaced copper ions (CuA and CuB) each
coordinated by three histidine ligands (type 3 copper site).
Figure 1D shows the crystal structure of a FU RtH2-e [22].
The different type of FUs share sequence identities of
around 45%. Being similar in primary, tertiary and quater-
nary structure, molluscan Hcs differ in their carbohydrate
content (between 2% and 9% (w/w)) and monosaccharide
composition [23]. Most probably the specific carbohydrate
content and composition of molluscan Hcs are the struc-
tural basis for the difference in their antigenicity.
Hemocyanins increase tumor cells apoptosis in vitro
To study the apoptotic effect of gastropodan Hcs on
tumor cells we tested their ability to influence directly theFigure 2 The gastropod Hcs RtH and HpH induce apoptosis of C-26 c
presence of different concentrations of HpH and RtH (100 μg/ml, 12.6 μg/m
cultivation the cells were double-stained with Annexin V-FITC /Propidium io
is shown in each quadrant. The panels represent the results from 3 indepeC-26 cells by apoptosis assay. C-26 carcinoma cells were
incubated with different amounts of HpH and RtH (ran-
ging from 0.1 μg/ml to 100 μg/ml). The cells were further
washed and the surface expression of phosphatidylserine
was studied at the 24 h, 48 h and 72 h of incubation. The
levels of induced early and late apoptosis as well as necro-
sis were analyzed by Annexin-V/Propidium iodide stain-
ing and flow cytometry.
A significant increase in percentage of early apoptosis
and a slight increase of late apoptosis were observed
after 48 hours of incubation with all tested amounts of
Hcs. In contrast, no obvious effect of the treatment was
found on the 24 h of incubation (data not shown).
High level of early apoptosis and considerable
enhancement in late apoptosis was observed on the 72 h
of incubation (Figure 2). Dose-dependant quantitative
corelation between induced apoptosis and Hcs added to
the cells was not found at all tested time points.
Tumor model development
For selection of proper C-26 murine colon carcinoma
model 4 groups of mice challenged with different cell
numbers were monitored (for details see Methods
section). Formation of solid tumors in all mice in the
group as well as 0% survival within 3 months after cells
challenge was the leading parameters for successful model
establishment. In the group inoculated with 5×105 cellsarcinoma cell line in vitro. The C-26 cells were incubated in the
l and 1.6 μg/ml) for 72 hours at 37°С/5% CO2. At the end of the
dide and were analyzed by flow cytometry. Percentage of stained cells
ndent experiments.
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challenge followed by 0% survival 3 months after cell chal-
lenge, which is acceptable for the model requested. In the
other groups mice developed tumors and died too early or
survived for longer period, so they weren’t appropriate for
further studies.Phenotyping of spleen and tumor suspensions
We have performed an immune system modulation
analysis during tumor development when the tumor model
was established to demonstrate the immune reaction to the
tumor growth. Spleens from mice challenged with 5×105
C-26 carcinoma cells or PBS treated only were isolated and
analyzed by flow cytometry. We observed a decrease of
CD4+, CD8+ (T cells), CD19+ (B cells) as well as CD94+
(NK cells and a subset of CD8+ T-cells) and slight increase
of CD14+ cells (monocytes, macrophages) compared to
PBS treated Balb/c mice (Figure 3A).Figure 3 FACS analysis of spleen and tumor suspensions. Spleens (A) an
were excised and the cell suspensions were incubated with one of the follow
anti-CD94-PE or anti-CD14-APC. Ten thousands cells were analyzed from each
5 experiments.A cell suspension prepared from solid tumors of the
studied mice showed presence of CD4+, CD8+, CD19+,
CD94+ as well as CD14+ cell populations in the tumor
microenvironment (Figure 3B). These results suggest a
movement of immune cells populations to the developed
tumors and a relevant decrease of the same populations
in the spleen of the animals.
Cytokine detection
TNFα, IFNγ, IL10 and IL4 levels were measured in mice
sera using Enzyme linked immunosorbent assay (ELISA)
kits. Challenge with 5×105 C-26 carcinoma cells and
treatment with RtH or HpH did not result in a signifi-
cant difference in the cytokine production between the
groups (data not shown).
Detection of anti- C-26 antibodies formation
Groups of Balb/c mice were treated with Hcs from
gastropods R. thomasiana and H. pomatia. Two groupsd solid tumors (B) from representative number of animals (n = 4 to 6)
ing anti-mouse antibodies - anti-CD4-APC, anti-CD8-FITC, anti-CD19-PE,
sample by flow cytometry. Data are representative of at least
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2 weeks before tumor cells inoculation and after estab-
lishment of palpable solid tumors the mice were injected
intratumoraly once weekly with RtH or HpH.
The other two groups (RtH, HpH) were inoculated
with 5×105 cells/mouse of C-26 cells and after palpable
solid tumor development the animals were injected once
a week with RtH or HpH. Mice injected with C-26 cells
only or PBS injected healthy mice were used as controls.
Collected sera from all studied groups were tested for
presence of anti-C-26 antibodies.
All groups developed anti-C-26 IgG antibodies com-
pared to the PBS treated control group (Figure 4A). The
titer of these antibodies decreased in C-26 group with-
out hemocyanin treatment during tumor development.
The level of anti-C-26 IgG antibodies in the groups
immunized with RtH and HpH without priming did not
differ compared to the level of C-26 control group for
the first 4 weeks after cell administration. Further treat-
ment with RtH or HpH prolonged persistence of highFigure 4 Detection of anti- C-26 antibodies and anti-C-26 antibody cr
treated with RtH or HpH (pretreated before C-26 inoculation with RtH, or H
C-26 cells without Hcs or mice treated only with PBS were used as control
according to the titer of standard anti-C-26 antibodies used for ELISA. The
Two-way ANOVA test (*p < 0.05; ***p < 0.001), in comparison to C-26 bearin
ELISA plates were coated with HpH or RtH (20 μg /ml) and after blocking t
C-26 colon carcinoma cells only or PBS healthy controls. The results are pre
each group.levels of anti-C-26 antibodies in the sera of these ani-
mals. A number of studies demonstrate the prolonged
survival in case of enhanced anti-tumor antibody pro-
duction [24].
The administration of RtH or HpH to sensRtH and
sensHpH groups resulted in a presence of anti-C-26
antibodies even before cell inoculation which higher
values were measured at the 4th week after C-26 injec-
tion (Figure 4A). To determine whether the recognition
of C-26 by antibodies generated after priming with Hcs
is due to polyspecificity we tested the sera specifisity to
foreign antigene (tetanus toxoid). We observed similar
pattern of anibody titers to the pattern of anti-C-26 in
all of the groups injected with Hcs (data not shown).
To examine the presence of cross-reactive epitopes in
Hc molecules and C-26 cells we set ELISA with the
HpH and RtH coated on the 96-well plates and incu-
bated with sera from animals challenged with C-26 cells
only. The results showed high levels of crossreactive IgG
antibodies to HpH and RtH in the sera of animals afteross-reactivity. (A) Anti- C-26 antibody levels in C-26 bearing-mice
pH, or not treated) were measured by ELISA. Mice inoculated with
groups. The results are presented as Relative Units (RU) calculated
data are presented as mean ± SD. p values are calculated using the
g mice. (B) ELISA assays for anti-C-26 antibody cross-reactivity. 96-well
he plates were incubated with diluted sera from mice inoculated with
sented as Relative Units (RU). Mean ± SD values were calculated for
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suggest the presence of crossreactive epitopes within
the hemocyanins and C-26 colon carcinoma cells. The
biochemical nature of these epitopes needs to be studied
and determined [25].
Survival and tumor manifestation
The survival of all tested groups was compared with the
survival of animals inoculated with C-26 cells only. The
results showed 15% survival of sensRtH group on week
15, 30% survival of the sensHpH group and over 30%
survival of the group treated with HpH compared to the
C-26 group while the group treated with RtH did not
show improved survival (Figure 5A).
The dynamics of tumor growth was monitored in all
Hcs treated groups and compared to the control group
(C-26 only). Animals injected with RtH and HpH with
or without priming developed small size tumors within
the whole period of observation (Figure 5B). HpH
treated group with no priming even showed a decrease
in the tumor growth at week 7th after C-26 challenge.
Histology and organ comparison
Splenomegaly is a characteristic feature of C-26 murine
tumor model [26]. Representative numbers of mice fromFigure 5 Tumor weight and survival. (A) Survival curves of studied anim
treated groups and compared to control group (C-26 only). The data are p
ANOVA test (*p < 0.05; **p < 0.01; ***p < 0.001), in comparison to C-26 beareach group were sacrificed for organ comparison and
examination. We observed a more than 3-fold significant
increase of the spleens in non treated C-26-bearing mice
compared to Hcs treated and mostly it was expressed in
sensHpH and sensRtH groups (Figure 6A).
Lungs from all studied groups were excised and the
levels of metastatic manifestation were compared to the
C-26 group. The Figure 6B shows large metastatic nod-
ules formed in the lungs of the control mice and also in
the RtH-treated group compared to the markedly inhib-
ited number of surface metastasis in the sensRtH,
sensHpH and in HpH treated groups.
We have examined morphological and histological
features of C-26 tumor model. The paraffin sections of
solid tumors from all studied groups were stained with
heamatoxilin-eosin histological staining technique and
were analyzed by light microscope. The tumor necrosis
indicates a poor prognosis for different cancers and is
associated with the survival. We observed differences
into the necrosis sections within the tumor mass of the
studied animals at 6th week of the treatment schedule.
In the sensRtH and sensHpH groups the levels of necro-
sis were less than in the RtH, HpH groups and also in
the group of animals bearing C-26 carcinoma cells only
(data not shown). These results could be associated withal groups. (B) The dynamics of tumor growth was monitored in all Hcs
resented as mean ± SD. The p-values are calculated using the Two-way
ing mice.
Figure 6 (See legend on next page.)
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Figure 6 Organ comparison. (A): Left panel: Spleen size comparison of PBS healthy control (A), C-26 bearing mice (B), C-26 bearing RtH treated animals
(C), C-26 bearing HpH treated animals (D), sens RtH mice (E), sens HpH mice (F). Right panel: the weights of the spleens from Hcs treated animals
compared to untreated mice. The data are presented as mean ± SD. The p-values are calculated using the Two-way ANOVA test (*p< 0.05; ***p < 0.001).
(B) Comparison of metastatic manifestations in the lungs of PBS healthy control (A); C-26 bearing mice (B), C-26 bearing RtH treated animals (C), C-26
bearing HpH treated animals (D), sens RtH mice (E), sens HpH mice (F). Data are representative of at least 3 independent experiments.
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sera of the hemocyanin-pretreated animals and with
prolonged survival of these groups.Discussion
There is a great need for new natural products and
compounds with anti-cancer effects. The nature-derived
substances can be formally separated into two groups i)
targeted on the development of the tumor itself such as
inhibitors of key for tumor growth molecules and ii)
molecules enhancing the ability of immune cells to
distinguish the non-self cancer cells and to induce ad-
equate and potent anti-cancer response. The majority of
them have high specificities and limited adverse effects
compared to common therapies. The results from the
current study confirm these statements.
Molluscan Hcs influence the apoptotic pathways of dif-
ferent cancer cell lines but the exact mechanisms are not
known [27,28]. McFadden et al. presumed that the tumor
suppressive effect of KLH could be mediated by alter-
ations in apoptotic pathways. They have demonstrated
that KLH has effect by increased apoptosis of SEG-1 cell
line (human Barrett’s esophageal adenocarcinoma) with
intact p53 tumor suppressive gene. On the other hand the
KLH shows no apoptotic effect on BIC-1 cells (Barrett’s
esophageal adenocarcinoma) with mutated p53 gene. It is
one possible mechanism for induced pro-apoptotic effect
of Hcs on the colon carcinoma cell line C-26 but this has
not been confirmed so far and further study needs to be
done.
Many authors performed proliferation assay (Wst8 or
MTT) with Hcs, but to study apoptotic effect of gastro-
podan Hcs on tumor cells by FACS is more precisely
[27,28]. In our hands we observed an increased apop-
tosis of tumor cells after Hcs treatment in vitro, but
always some cells remained unaffected. The extensive
proliferation of these unaffected cells could mask the
Hcs treatment results.
C-26 carcinoma cells challenged Balb/c mice had a
decrease of CD4+, CD8+, CD19+ as well as CD94+ cells
in the spleen compared to PBS treated ones. In contrast,
we have observed a presence of tumor-infiltrating lym-
phocytes, which can explain the migration of these cell
populations from the spleen.The immunization with RtH or HpH did not result in a
significant difference in the cytokine profiles (TNFα, IFNγ,
IL10, IL4) between the groups.
The presence of anti-C-26 antibodies generated after
priming with RtH or HpH even before C-26 cell chal-
lenge could be explained with production of polyspecific
antibodies recognizing Hc molecules or with existence
of crossreactive epitopes on the surfaces of C-26 carcin-
oma cells and Hcs. Such epitope was already detected
on the SBC cells and KLH [25]. It was observed a cross-
reactivity of anti-Hc antibodies to the tetanus toxoid
and C-26 cells. This result reveals a broad spectrum
of polyspecificity of generated antibodies after Hc
administration.
In the beginning of Hcs administration some of the
treated mice exhibited worse survival rate than the
untreated ones. Finally, in the end-point HpH treated
groups had better performance and exhibited improved
survival compared to the control group. This observa-
tion illustrates that improvement of several clinical pa-
rameters (anti-C26 Antibodies development, reduction
of metastatic manifestation and spleen size) does not
always prolong survival.Conclusion
The Hcs - treated animals had prolonged survival and
inhibited tumor growth, splenomegaly and lung metas-
tasis appearance. These huge proteins can induce a vig-
orous anti-tumor adaptive immune response. Taken
together our findings demonstrate that the Hcs isolated
from different arthropod and mollusc species could be
used as pro-apoptotic agents able to improve humoral
anti-cancer response and moderate the manifestation of
C-26 carcinoma symptoms.Methods
Mice
Female 10 weeks old Balb/c mice were obtained from
Harlan Farm, Blackthorn, UK. The animals were kept
under specific pathogen free (SPF) conditions and the ma-
nipulations were approved by the Committee on Animal
Research and Ethics at the Bulgarian Food Safety Agency -
Ministry of Agriculture and Food in accordance with the
international regulations.
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FITC (Fluorescein isothiocyanate) -conjugated anti-mouse
CD8, PE (Phycoerythrin) -conjugated anti-mouse CD94
and anti-mouse CD19 and APC (Allophycocyanin) –
conjugated anti-mouse CD4 mAbs (eBioscience,
Frankfurt, Germany) were used for FACS (Fluorescence-
activated cell sorting) experiments. AP (Alkaline phos-
phatase) –conjugated anti-mouse IgG (Sigma-Aldrich,
Taufkirchen, Germany) were used for ELISA.
Cell line
Murine colon carcinoma cell line C-26 (CT26.WT
(ATCC® CRL-2638™)) was cultured in complete RPMI
(Roswell Park Memorial Institute medium) 1640 medium
(Gibco, Gaithersburg, MD) containing 10% FCS (fetal calf
serum), 4 mM L-glutamine, 50 μM 2-mercaptoethanol
and antibiotics at 37°С/5% CO2. The confluent monolayer
cells (90%) were trypsinized and used for animal adminis-
tration and solid tumor establishment.
C-26 cell lysate preparation
C-26 cell line was cultured in complete RPMI 1640
medium (see above) and 90% confluent cell monolayer was
trypsinized and centrifuged (110 × g, 10 min, 4°C). The pel-
let was collected and was put under 8-fold cycles of freeze-
thaw (from −80°C to 37°C). After centrifugation (110 × g,
2 min) the supernatant was kept and the total protein was
determined spectrophotometrically at λ = 280 nm.
Isolation and purification of hemocyanins
RtH was isolated from the hemolymph of marine
gastropod Rapana thomasiana as described in [29].
HpH was isolated from the hemolymph of terrestrial
snails Helix pomatia according to [30]. The HpH was
solubilized in 100 mM sodium acetate buffer, pH 5.7,
and the β-Hc isoform precipitated by dialysis of HpH
against 10 mM sodium acetate buffer, pH 5.3, as de-
scribed elsewhere [31]. Then β-HpH was solubilized in
100 mM sodium phosphate buffer, pH 6.5, at a concen-
tration of 27 mg/ml (stock solution).
RtH and β-HpH were further purified by gel filtration
chromatography on a Sepharose 4B column (90 ×
2.4 cm), equilibrated and eluted with 50 mM PBS buffer,
pH 7.2. The purity of isolated RtH and β-HpH was
controlled by SDS- and native PAGE as described in
[29,31], and by transmission electron microscopy [32].
The protein concentrations were determined spectro-
photometrically using the specific absorption coefficient
A278°
.1% = 1.36 mg−1 ml cm−1 (20°C) for RtH (27) and
A278°
.1% = 1.416 mg−1 ml cm−1 (20°C) for β-HpH [33],
respectively.
Hc solutions were passed once through a Detoxi-Gel
column in order to remove endotoxin contaminations
(Detoxi-Gel column, Thermo Fisher Scientific, Rockford).The level of the remaining endotoxin was determinated by
Limilus Amebocyte Lysate coatest gel (LAL) (Chromogenix
AB, Molndal, Sweden).
Apoptotic assay
The C-26 cells were cultured in complete RPMI 1640
medium and 90% confluent cell monolayer was incubated
in the presence of different concentrations of HpH and
RtH (100 μg/ml, 12.6 μg/ml, 1.6 μg/ml and 0.1 μg/ml) for
24, 48 and 72 hours at 37°С/5% CO2. Then cells were col-
lected, washed and stained with Annexin V-FITC apoptosis
detection Kit I (BD Biosciences Pharmingen, Erenbodegem,
Belguim), containing Propidium iodide as DNA-binding
dye according manufacturer’s instruction. The apoptosis of
gated cells was analyzed within 15 minutes using flow
cytometry (BD LSR II flow cytometer). The early (AnnV-
FITC+, PI-) and late (AnnV-FITC+, PI+) apoptosis, as well
as necrosis (AnnV-FITC-, PI+) were measured at different
intervals (24, 48 and 72 h of incubation).
Tumor model establishment
Four groups of Balb/c mice (10 animals each) were
challenged s.c. in the right flanks with different number of
C-26 murine carcinoma cells ( 1×104, 1×105, 5×105, 5×106
cells/mice). The animals were observed for 14 weeks.
Treatment schedule
Two groups of female Balb/c mice (20 animals per
group) were injected with RtH (sensRtH) or HpH
(sensHpH) (200 μg/mouse, i.p.) 2 weeks before tumor
cells inoculation (5×105 cells/mouse). After palpable
solid tumor establishment the animals were injected
intratumoraly once weekly with 100 μg/mouse of RtH or
HpH, respectively. Another two groups were inoculated
with C-26 cells (5×105 cells/mouse) and after palpable
solid tumor development the mice were injected every
week with RtH (RtH group) or with HpH (HpH group)
(100 μg/mouse, intratumoraly). Control groups of mice
were challenged with C-26 cells or PBS only. Another
two control groups were injected once weekly with RtH
or HpH only (100 μg/mouse, i.p.). Tumor growth was
monitored by measuring palpable solid tumors once a
week with a microcaliper and the tumor volume was de-
termined. Every two weeks the animals from all groups
were bled and the sera were kept frozen at −70°C. All
experiments were duplicated.
Flow cytometry analysis for phenotyping of spleen and
tumor suspensions
Spleens and solid tumors from representative number of
animals (n = 4 to 6) were taken and monocellular sus-
pension was isolated by cell strainers (BD Biosciences,
Erenbodegem, Belguim). The cells were washed with
PBS (containing 2.5% FCS and 0.05% sodium azide) and
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bodies - anti-CD4-APC, anti-CD8-FITC, anti-CD19-PE,
or anti-CD94-PE. Each incubation step was performed
for 30 min at 4°C. Finally, the cells were washed twice and
kept at 4°C. Ten thousands cells were analyzed from each
sample with a BD LSR II flow cytometer using the Diva
6.1.1. software (BD Biosciences, San Jose, CA).Cytokine quantification
TNFα, IFNγ, IL10 and IL4 levels were measured in
mouse sera using ELISA sets (BD OptEIA™, BD Biosci-
ences Pharmingen, Erenbodegem, Belguim) according to
the manufacturer’s instructions.ELISA assays
ELISA assays for anti-C-26 and anti-TT IgG antibodies
96-well plates (Nunc, Roskilde, Denmark) were coated
with C-26 lysate (150 μg/ml) or with tetanus toxoid (TT)
(20 μg/ml, from Bulbio, Sofia, Bulgaria) diluted in coating
buffer (NaHCO3, pH 9,6) by incubation overnight at 4°C.
The plates were washed with PBS/0.05% Tween 20 and
blocked with 1%BSA in PBS for two hours at room
temperature. After washing diluted serum samples from
different groups of animals were added and incubated for
1 hour at room temperature. The plates were then
washed, incubated for 1 hour at room temperature with
alkaline phosphatase-labelled goat anti-mouse IgG and de-
veloped by alkaline phosphatase substrate pNPP (p-Nitro-
phenyl Phosphate). After washing the absorbance was
measured at 405 nm. The obtained ELISA results were
presented as relative units (RU), corresponding to the titer
of anti-C-26 or anti-TT standard antibodies used for
ELISA.ELISA assays for anti-C-26 antibody cross-reactivity
Another 96-well plates were coated with HpH or RtH
(20 μg/ml) in coating buffer overnight at 4°C. After block-
ing, the plates were incubated with diluted sera from mice
inoculated with C-26 colon carcinoma cells only. Plates
were then developed as described above.Histology and organ comparison
Solid tumors were resected from terminal animals. After
fixation in phosphate-buffered formalin (10%) the tis-
sues were embedded in paraffin and 7 μm sections were
analyzed using a standard haematoxylin/eosin staining
technique.
Spleens, kidneys, livers and lungs were taken from the
same animals and were compared with organs from
healthy mice for size differences 8 weeks after the tumor
cell administration.Statistical analysis
The values in figures correspond to mean ± SD. The
Two-way ANOVA test was used to determine differences
between each two groups. A value of P < 0.05 was consid-
ered as statistically significant. Survival significance was de-
termined via analysis of survival curves with Prism software
from GraphPad (San Diego, CA).
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